What it is
Testagen is a Khavinson-class bioregulator tied to the Russian prostate/testicular peptide literature.
Evidence boundary
Evidence is concentrated in Russian bioregulator literature, with little independent replication and no verified human dosing protocol.
Trial evidence
- PMID 22117547 — Penetration of short fluorescence-labeled peptides into the nucleus in HeLa cells and in vitro specific interaction of the peptides with deoxyribooligonucleotides and DNA.
Preparation and measurement
Reconstitution: 20 mg vial + 3 mL BAC = 6.67 mg/mL.
Concentration matches.
Reference schedule
| Phase | Dose | Draw / measure | Frequency | Weekly total |
|---|---|---|---|---|
| Days 1–20 (cycle on) | 500 mcg | 7.5 U (0.075 mL) | Once daily during cycle (20 days on / 4–6 months off) | 3.5 mg/week |
| Months 1–6 (cycle off) | 0 mcg | 0 U (no draw) | Off | 0 |
Days 1–20 (cycle on)
- Dose
- 500 mcg
- Draw / measure
- 7.5 U (0.075 mL)
- Frequency
- Once daily during cycle (20 days on / 4–6 months off)
- Weekly total
- 3.5 mg/week
Months 1–6 (cycle off)
- Dose
- 0 mcg
- Draw / measure
- 0 U (no draw)
- Frequency
- Off
- Weekly total
- 0
Weekly totals apply only during the active phase.
Titration rules
-
Days 1–20 (cycle on): 500 mcg/day. Once daily during the 20-day active phase.
-
Cycle structure: 20-day active phase, 4–6 month rest. 1–2 cycles per year is standard.
-
Timing: Once daily during active phase; time of day flexible. Rotate injection sites.
-
Whether the name is being used for a different compound
-
Regional literature only
-
The lack of a verified human protocol
-
Route and dilution assumptions that are not source-backed
Practical rules
- Keep it as a literature note unless a real protocol appears.
- Avoid presenting daily dosing as established fact.